MICHAEL HAMILL, Ph.D.
VICE PRESIDENT, RESEARCH
Mike Hamill, Ph.D., leads the Research division at Axcella which includes the Discovery and the Axcellerator platform development teams.
He joined Axcella in 2011 as part of the founding scientific team, gaining experience across R&D, and assuming positions of increasing responsibility and leadership within the company.
In the course of developing the Axcellerator Platform, Dr. Hamill led the Research teams at Axcella through product innovation and design and the initial designation of product candidates through the determination of priority disease indications. Dr. Hamill is responsible for the exploration of various disease opportunities to determine next steps in DAAC development and program launch within Axcella’s extensive, and ever-expanding pipeline.
Dr. Hamill is an inventor or author of more than 100 key patents, patent applications and peer-reviewed journals. Dr. Hamill began his industry career at Scynexis (NASDAQ: SCYX) as a Synthetic Chemist before joining Virdante Pharmaceuticals as an Analytical Chemist, where he engineered glycans on antibodies.
During his academic career, Dr. Hamill characterized the role of novel enzymes containing organic and inorganic redox cofactors. Dr. Hamill received a Ph.D., in biochemistry from Boston University, where he studied the structural and enzymatic properties of multiple novel flavoenzymes. Following his Ph.D., Mike completed a post-doctoral fellowship at the Massachusetts Institute for Technology where he studied iron-sulfur cluster enzymes. Dr. Hamill also holds a Bachelor’s degree in Chemistry from Gettysburg College.